PAVmed completed a $45 million financing to strengthen its capital structure and eliminate legacy convertible securities, enhancing its cash runway. The company relaunched its medical device portfolio under new leadership and licensed new technology from Duke University. Its subsidiary Veris Health advanced its partnership with Ohio State University and is progressing an implantable physiological monitor toward a planned FDA submission in late 2026. Lucid Diagnostics expanded access to its EsoGuard esophageal cancer test, secured a VA contract, and reported $1.5 million in Q4 revenue. These developments position PAVmed for growth across its diversified medical technology businesses.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
